Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Trial details
- Registry ID
- NCT02464228
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as R115777; Zarnesta; Zarnestra
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard TherapyNCT02464228 | KURA | Phase 2 | Completed | 2021-03-31Actual |
| Tipifarnib in Subjects With Myelodysplastic SyndromesNCT02779777 | KURA | Phase 2 | Terminated | 2018-08-28Actual |
| Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS MutationsNCT02383927 | KURA | Phase 2 | Completed | 2020-12-14Actual |
| Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid LeukemiaNCT02807272 | KURA | Phase 2 | Completed | 2020-11-30Actual |
| Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to TherapyNCT03719690 | KURA | Phase 2 | Completed | 2023-05-02Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |